Effect of human renal and hepatic disease on the pharmacokinetics of anticancer drugs
- 30 June 1982
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 9 (2), 85-124
- https://doi.org/10.1016/s0305-7372(82)80012-1
Abstract
No abstract availableThis publication has 123 references indexed in Scilit:
- Determination of N-(Phosphonacetyl)-l-Aspartic acid (PALA) in plasma and urine by high pressure liquid chromatographyEuropean Journal of Cancer (1965), 1980
- Decreased half life of cyclophosphamide in patients under continual treatmentEuropean Journal of Cancer (1965), 1979
- Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant diseaseEuropean Journal of Cancer (1965), 1978
- Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearanceJournal of Pharmacokinetics and Biopharmaceutics, 1977
- Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate ToxicityNew England Journal of Medicine, 1977
- Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal functionCancer, 1977
- Plasma half-life of cytosine arabinoside in patients with leukaemia—the effect of uridineEuropean Journal of Cancer (1965), 1975
- Hydroxylation of the carcinostatic 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) by rat liver microsomesBiochemical and Biophysical Research Communications, 1974
- Clearance concepts in pharmacokineticsJournal of Pharmacokinetics and Biopharmaceutics, 1973
- The effect of neoplastic and allied diseases on the concentrations of the plasma proteinsCancer, 1950